43,685 Shares in Zoetis Inc. $ZTS Acquired by Sienna Gestion

Sienna Gestion bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 43,685 shares of the company’s stock, valued at approximately $5,828,000.

Several other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC grew its holdings in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after buying an additional 1,224 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares in the last quarter. Finally, Sigma Planning Corp boosted its position in shares of Zoetis by 3.1% in the second quarter. Sigma Planning Corp now owns 3,325 shares of the company’s stock valued at $518,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $121.54 on Monday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $51.31 billion, a P/E ratio of 20.19, a PEG ratio of 1.85 and a beta of 0.95. The stock has a 50-day moving average price of $126.06 and a 200-day moving average price of $132.88. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZTS. Barclays initiated coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. UBS Group set a $136.00 price target on shares of Zoetis in a research report on Thursday, January 29th. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Bank of America lifted their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Finally, KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.